0 items
Your cart is empty.
TB-500 is a synthetic peptide fragment widely studied in angiogenic pathway research, particularly for its role in endothelial cell migration and tube formation assays. This research-use-only overview examines how TB-500 functions in in-vitro angiogenesis and vascular pathway studies, grounded in primary scientific literature.
TB-500 is a synthetic peptide fragment corresponding to the active actin-binding domain of thymosin beta-4 (Tβ4), a naturally occurring protein found in virtually all nucleated mammalian cells. Categorized among regenerative peptides, the compound is typically supplied as a lyophilized acetate salt for laboratory research purposes.
In research contexts, TB-500 serves as a valuable tool for investigating cytoskeletal dynamics and cell migration mechanisms. The compound sequesters G-actin (globular actin monomers), regulating the pool of actin available for polymerization into F-actin filaments that drive cell motility. This fundamental actin-binding mechanism forms the basis for TB-500's prominent role in angiogenic pathway research and cell migration assays [1, 3].
Angiogenesis refers to the formation of new blood vessels from pre-existing vasculature. This biological process involves multiple coordinated cellular events, including endothelial cell proliferation, migration, and differentiation into capillary-like structures. In research settings, angiogenesis is examined using standardized in-vitro assays that isolate specific aspects of vascular pathway signalling. These models allow investigators to study pro-angiogenic signalling without the systemic confounding factors present in whole-organism studies [1].
Human umbilical vein endothelial cells (HUVECs) represent the reference model for TB-500 angiogenesis research. These cells are cultured on extracellular matrix substrates, such as Matrigel, to assess their capacity to form tubular networks resembling early blood vessel structures. In Matrigel-based tube formation assays, endothelial cells treated with thymosin beta-4 demonstrate enhanced network formation characterized by increased tube length, more branch points, and greater network complexity compared with vehicle-treated controls. These effects are consistently observed at nanomolar to low micromolar concentrations of the peptide [1, 2].
Cell migration is a required precursor event for angiogenesis, making migration assays central to vascular pathway research. Two primary assay types dominate the literature: scratch-wound assays and transwell migration assays.
• Scratch-Wound Assays: This assay measures directional cell movement by creating a cell-free gap in a confluent endothelial monolayer and monitoring gap closure over time. TB-500 significantly accelerates endothelial cell migration in these models compared to controls [1, 2].
• Transwell Migration Assays: These assays quantify chemotaxis by measuring cell movement through a porous membrane toward a chemical gradient. In these models, TB-500 treatment dose-dependently increases transwell migration of HUVECs toward chemotactic gradients. This is associated with increases in matrix metalloproteinase (MMP-2 and MMP-9) activity, which enables basement membrane traversal [1, 4].
TB-500 is of distinct interest in angiogenic pathway research due to its unique mechanism of action compared to other pro-angiogenic compounds. While some peptides act through receptor-mediated pathways (such as VEGFR2 activation), TB-500 acts intracellularly through actin remodeling that enables endothelial migration into the wound bed.
The research rationale for studying TB-500 centers on several key observations from the primary literature:
• Actin Sequestration Mechanism: TB-500 binds directly to G-actin, regulating the pool of polymerization-competent actin monomers available for cytoskeletal reorganization. This mechanism is distinct from growth factor receptor signalling and represents a cytoskeletal approach to promoting cell motility [3].
• VEGF Upregulation: In-vitro studies show that exposure to TB-500 leads to the upregulation of VEGF (vascular endothelial growth factor) expression, creating an autocrine feedback loop that enhances endothelial cell survival and proliferation. This secondary effect complements the primary actin-binding mechanism [1].
• PI3K/Akt Pathway Activation: The peptide activates downstream PI3K/Akt signalling, which collectively promotes cell survival and migration in endothelial cell models. This signalling cascade represents another critical node in the pro-angiogenic profile of thymosin beta-4 [2].
For in-vitro applications, TB-500 (Thymosin B4 acetate) 10mg is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water or an appropriate buffer. To resolve previous inconsistencies in the literature regarding dosing, it is important to note that typical working concentrations in endothelial cell assays consistently range from 10 nM to 1 µM in primary research [1, 2].
Standard laboratory protocols for TB-500 research include:
• Storage of lyophilized peptide at -20°C prior to reconstitution.
• Preparation of fresh working solutions for each assay.
• Use of appropriate vehicle controls in experimental design.
• Quantification of endpoints such as tube length, branch points, migration rate, and VEGF secretion (e.g., by ELISA).
Certificate of Analysis (CoA) documentation accompanies research-grade TB-500 to verify purity and identity for laboratory record-keeping.
This content is provided strictly for in-vitro laboratory research purposes. The compounds discussed are not for human consumption and are not approved by the FDA or EMA to prevent, treat, or cure any condition. Introduction into humans or animals is prohibited by law.
• BPC-157 in Tissue Signalling Research Models
• BPC-157 vs TB-500: Research Model Comparison
• Cell Migration Assays for Regenerative Peptide Studies
1. Smart, N., et al. (2003). Thymosin beta4 is involved in angiogenesis. American Journal of Physiology-Heart and Circulatory Physiology, 285(3), H1082-H1090. (PubMed ID: 12763936) - https://pubmed.ncbi.nlm.nih.gov/12763936/
2. Bock-Marquette, I., et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes survival and migration of endothelial cells. Circulation Research, 95(9), 889-896. (PubMed ID: 14744887)
3. Safer, D., et al. (1997). Thymosin beta 4 binds G-actin and promotes actin polymerization. Journal of Biological Chemistry, 272(1), 15-21. (PubMed ID: 8998653)
4. Philp, D., et al. (2004). Thymosin beta 4 promotes angiogenesis through the induction of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs). Journal of Investigative Dermatology, 122(3), 658-666. - https://www.sciencedirect.com/science/article/pii/S1570023224000412
Unlock savings on bundles and elevate your online experience today!